[go: up one dir, main page]

GT200300227A - Formulaciones de liberacion prolongada en forma de suspension - Google Patents

Formulaciones de liberacion prolongada en forma de suspension

Info

Publication number
GT200300227A
GT200300227A GT200300227A GT200300227A GT200300227A GT 200300227 A GT200300227 A GT 200300227A GT 200300227 A GT200300227 A GT 200300227A GT 200300227 A GT200300227 A GT 200300227A GT 200300227 A GT200300227 A GT 200300227A
Authority
GT
Guatemala
Prior art keywords
prolonged release
suspension
release formulations
prepare
release formulation
Prior art date
Application number
GT200300227A
Other languages
English (en)
Inventor
Jaymin Chandrakant Shah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200300227A publication Critical patent/GT200300227A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN KIT FARMACEUTICO PARA PREPARAR UNA FORMULACION DE LIBERACION PROLONGADA INYECTABLE DE UN COMPUESTO FARMACEUTICO TAL COMO ZIPRASIDONA Y UN PROCEDIMIENTO PARA PREPARAR DICHA FORMULACION DE LIBERACION PROLONGADA.
GT200300227A 2002-10-25 2003-10-21 Formulaciones de liberacion prolongada en forma de suspension GT200300227A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42129502P 2002-10-25 2002-10-25

Publications (1)

Publication Number Publication Date
GT200300227A true GT200300227A (es) 2004-06-23

Family

ID=32176696

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200300227A GT200300227A (es) 2002-10-25 2003-10-21 Formulaciones de liberacion prolongada en forma de suspension

Country Status (21)

Country Link
US (1) US20040146562A1 (es)
EP (1) EP1562546A1 (es)
JP (2) JP2006505579A (es)
KR (1) KR20050071611A (es)
CN (1) CN1703198A (es)
AR (1) AR041826A1 (es)
AU (1) AU2003267763A1 (es)
BR (1) BR0315663A (es)
CA (1) CA2498276A1 (es)
GT (1) GT200300227A (es)
MX (1) MXPA05004299A (es)
NL (1) NL1024616C (es)
NO (1) NO20051187L (es)
PA (1) PA8586301A1 (es)
PE (1) PE20040471A1 (es)
PL (1) PL375603A1 (es)
RU (1) RU2292207C2 (es)
TW (1) TW200418477A (es)
UY (1) UY28035A1 (es)
WO (1) WO2004037224A1 (es)
ZA (1) ZA200501979B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
UA79984C2 (en) * 2002-08-20 2007-08-10 Bristol Myers Squibb Co Preparation on the basis of aripiprazole complex and use thereof
CN101797221B (zh) 2002-12-13 2013-06-12 杜雷科特公司 包含高粘度液体载体材料的口服递药系统
JP2007522095A (ja) * 2003-05-16 2007-08-09 ファイザー・プロダクツ・インク ジプラシドンを用いた不安の治療
WO2006000913A1 (en) * 2004-06-23 2006-01-05 Pfizer Products Inc. Method for sterile filtration of viscous pharmaceutical compositions
DK2767292T3 (en) * 2004-09-17 2016-12-19 Durect Corp RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB
EP1855651A4 (en) * 2005-03-03 2011-06-15 Elan Pharma Int Ltd NANOPARTICLE COMPOSITIONS OF HETEROCYCLIC AMID DERIVATIVES
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
CN100391458C (zh) * 2006-02-07 2008-06-04 上海医药工业研究院 齐拉西酮或其盐包合物制备方法
AU2007248949B2 (en) * 2006-05-09 2010-04-08 Astrazeneca Ab Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
EP2484347A1 (en) 2006-11-03 2012-08-08 Durect Corporation Transdermal delivery systems comprising bupivacaine
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
TW201521769A (zh) 2013-03-15 2015-06-16 Durect Corp 具有流變改質劑以減少溶解變異性之組成物
MY205229A (en) 2016-07-06 2024-10-08 Durect Corp Oral dosage form with drug composition, barrier layer and drug layer
US11197850B2 (en) * 2017-02-23 2021-12-14 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Powder injection of the donepezil semi palmoxiric acid salt, composition containing same and preparation method therefor
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989002265A1 (fr) * 1987-09-07 1989-03-23 Teijin Limited Emulsion grasse contenant un medicament, du type prepare immediatement avant l'utilisation, et procede de preparation d'une telle emulsion grasse contenant un medicament
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5594141A (en) * 1994-11-23 1997-01-14 Neurogen Corporation Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands
US6040295A (en) * 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
ATE277641T1 (de) * 1996-05-07 2004-10-15 Pfizer Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
PT949905E (pt) * 1996-12-20 2001-12-28 Alza Corp Composicao de gel injectavel de efeito retardado e processo para a sua preparacao
HUP0003393A3 (en) * 1997-05-16 2001-03-28 Amgen Inc Thousand Oaks Ustained-release delayed gels
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
EA003907B1 (ru) * 1999-05-27 2003-10-30 Пфайзер Продактс Инк. Композиция зипразидона в виде суспензии
MY137726A (en) * 2000-11-22 2009-03-31 Nycomed Gmbh Freeze-dried pantoprazole preparation and pantoprazole injection
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2005508625A (ja) * 2001-08-31 2005-04-07 ザ ロックフェラー ユニバーシティー 抗精神病薬の分類方法

Also Published As

Publication number Publication date
JP2006505579A (ja) 2006-02-16
JP2006219501A (ja) 2006-08-24
MXPA05004299A (es) 2005-08-03
PE20040471A1 (es) 2004-08-14
KR20050071611A (ko) 2005-07-07
NL1024616A1 (nl) 2004-04-27
ZA200501979B (en) 2006-04-26
PL375603A1 (en) 2005-12-12
CA2498276A1 (en) 2004-05-06
EP1562546A1 (en) 2005-08-17
AU2003267763A1 (en) 2004-05-13
TW200418477A (en) 2004-10-01
WO2004037224A1 (en) 2004-05-06
UY28035A1 (es) 2004-05-31
BR0315663A (pt) 2005-08-30
CN1703198A (zh) 2005-11-30
NL1024616C (nl) 2010-04-19
NO20051187L (no) 2005-04-11
AR041826A1 (es) 2005-06-01
RU2005112202A (ru) 2005-11-20
PA8586301A1 (es) 2004-05-07
RU2292207C2 (ru) 2007-01-27
US20040146562A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
GT200300227A (es) Formulaciones de liberacion prolongada en forma de suspension
ECSP088345A (es) Nuevas pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina
UY30495A1 (es) Formulaciones de modificador de respuesta inmune
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
HN2012001162A (es) Triazolopiridinas
CR20140274A (es) Formulaciones de pepticuerpos terapéuticos liofilizados
TW200744602A (en) Administration of dipeptidyl peptidase inhibitors
CR9262A (es) Formulaciones en tableta de cci-1179 oralmente biodisponibles
AU308855S (en) Camera
GT200500314A (es) Formulaciones
DK1641803T3 (da) Thienopyrimidinderivater som kaliumkanalinhibitorer
HN2003000206A (es) Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
AR048963A1 (es) Formulaciones de interferon de hidrogel de poloxamero
ECSP11005642A (es) Nuevos pirazolopirimidinas como inhibidores de quinasa dependientes de ciclinas
HN2009003296A (es) Una composicion de liberacion prolongada que comprende un derivado de somatostatina en microparticulas
ECSP10010576A (es) Formulaciones orales e inyectables de compuestos de tetraciclina
CL2008002082A1 (es) Compuestos derivados de 6-fenil-1h-imidazo[4,5-c]piridina-4-carbonitrilo, inhibidores de catepsina s y catepsina k; composicion farmaceutica; y uso en el tratamiento de osteoporosis, aterosclerosis, inflamacion, entre otras enfermedades.
GT200400257A (es) Composicion herbicida
PA8654701A1 (es) Indoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
MX2009012370A (es) Formulacion de antraciclina de baja viscosidad.
SI1638582T1 (sl) Uporaba hialuronske kisline za pripravo sestav za zdravljenje ponavljajoäśih se aft v ustni votlini
ITMI20031714A1 (it) Formazioni ad azione antitumorale.
SG165404A1 (en) Fulvestrant formulation
GT200800297A (es) Formulaciones galenicas de alisquireno e hidroclorotiazida